Angeion Rolls Out Lyra 2020 ICD At ACC Following FDA Approval March 5
This article was originally published in The Gray Sheet
Executive SummaryFDA's March 5 sign-off on a premarket approval application supplement for Angeion's single-chamber Lyra 2020 implantable cardioverter defibrillator allowed for a timely launch of the product at the American College of Cardiology's 48th Annual Scientific Sessions, March 7-10 in New Orleans.
You may also be interested in...
The European Court of Justice has confirmed the European Medicines Agency’s approach to disclosure of data submitted as part of a marketing authorization application. It is a big disappointment for industry, which nonetheless says it supports responsible data sharing and will support efforts to develop a balanced approach.
Dr Reddy’s sees its Indian domestic market and China as hot prospects as it pursues its “transformation journey” in which it is reducing its dependence on the slowing US market.